#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14154	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2166	651.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1770	1770	T	795	T,C	723,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14154	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2166	651.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1504	1504	C	824	C	761	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26272	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3527	742.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1662	1662	A	874	A	811	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26272	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3527	742.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2296	2296	C	864	C,T	786,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26272	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3527	742.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2370	2370	A	842	A	778	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26272	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3527	742.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2922	2922	C	813	C	754	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2116	folP	855	855	100.0	folP.l15.c30.ctg.1	1661	126.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1085	1087	AGC	216;214;216	A,G;G;C	197,1;197;199	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5450	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3259	166.3	1	SNP	p	S91F	1	.	.	271	273	TTC	525	527	TTC	194;192;191	T;T;C	180;177;179	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5450	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3259	166.3	1	SNP	p	G95N	0	.	.	283	285	GGC	537	539	GGC	186;184;186	G;G;C	169;167;170	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5450	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3259	166.3	1	SNP	p	D95G	1	.	.	283	285	GGC	537	539	GGC	186;184;186	G;G;C	169;167;170	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1630	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1412	114.8	1	SNP	p	G45D	0	.	.	133	135	GGC	587	589	GGC	200;201;202	G;G;C	187;187;190	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	848	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	977	86.5	0	.	n	.	0	A197.	DEL	197	197	A	539	539	A	213	A	195	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4992	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	167.1	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1451	1453	GTC	214;212;212	G;T;C	197;194;195	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4992	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	167.1	1	SNP	p	D86N	0	.	.	256	258	GAC	557	559	GAC	222;221;222	G;A,T;C	201;193,2;200	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4992	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	167.1	1	SNP	p	S87R	1	.	.	259	261	CGT	560	562	CGT	221;225;225	C;G;T	202;204;205	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4992	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	167.1	1	SNP	p	R87W	0	.	.	259	261	CGT	560	562	CGT	221;225;225	C;G;T	202;204;205	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4992	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	167.1	1	SNP	p	R87I	0	.	.	259	261	CGT	560	562	CGT	221;225;225	C;G;T	202;204;205	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4992	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	167.1	1	SNP	p	S88P	0	.	.	262	264	TCC	563	565	TCC	226;227;228	T;C;C	206;209;211	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4524	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2494	180.5	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1297	1299	TGC	214;211;212	T;G;C,A	196;195;197,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4524	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2494	180.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1507	1509	GGC	234;235;235	G;G;C	212;209;210	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1216	1218	GCA	225;221;216	G;C,T;A	207;206,1;201	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1219	1221	ATC	211;206;208	A;T;C	196;191;193	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1231	1233	GTG	216;216;214	G;T;G	203;201;201	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1231	1233	GTG	216;216;214	G;T;G	203;201;201	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1735	1737	ACC	234;233;232	A;C;C,T	212;213;215,2	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1789	1791	GCG	189;189;186	G;C,G;G	167;143,1;150	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1789	1791	GCG	189;189;186	G;C,G;G	167;143,1;150	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1912	1914	GGC	189;189;190	G;G;C	177;171;177	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1921	1923	GGC	186;184;184	G;G;C	174;171;172	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3998	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2331	170.4	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1939	1941	TCG	179;188;182	T,G;C;G	119,9;152;151	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5754	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3083	186.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1578	1580	CCG	264;262;262	C;C;G	230;238;231	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2328	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1727	134.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	559	559	C	175	C	157	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	298	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	556	27.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	410	412	ACG	83;83;81	A;C;G	75;75;73	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	298	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	556	27.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	452	454	CAA	38;35;30	C;A;A	31;31;28	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	298	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	556	27.6	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	458	460	TAC	28;25;24	T;A;C	26;24;24	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	470	472	GAA	255;253;251	G;A;A	237;235;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	758	760	GAT	262;261;263	G;A;T	238;237;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	881	883	TCA	244;247;246	T;C;A	224;228;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	K208_I209del	DEL	622	622	A	979	979	A	204	A	199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	D212N	NONSYN	634	636	GAT	986	988	AAT	205;210;207	A;A;T	199;204;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1004	1006	GTC	196;195;193	G;T;C	187;186;186	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1334	1336	GCA	144;145;146	G;C;A	132;131;133	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1349	1351	GTC	129;132;133	G;T;C	123;123;125	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	1	SNP	p	G120K	1	.	.	358	360	AAG	716	718	AAG	257;259;259	A;A;G	234;235;234	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	1	SNP	p	A121D	1	.	.	361	363	GAC	719	721	GAC	257;257;260	G;A;C,T	230;228;232,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1543	167.3	1	SNP	p	D121N	0	.	.	361	363	GAC	719	721	GAC	257;257;260	G;A;C,T	230;228;232,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10302	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4789	214.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1940	1942	AAT	218;217;218	A;A;T	207;206;203	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1160	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1030	112.2	1	SNP	p	V57M	1	.	.	169	171	ATG	551	553	ATG	256;258;258	A,T;T;G,A	239,1;240;239,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
